Skip to main content
Premium Trial:

Request an Annual Quote

Melanie Mahtani, Kevin King

Premium
Melanie Mahtani has been named executive advisor of commercial development at Med BioGene.
 
Mahtani was most recently vice president of corporate business development at Panomics where she led the company's strategic partnering activities with diagnostics, pharmaceutical, and biotechnology companies. Before Panomics, Mahtani served as director of microarray systems R&D at Amersham Biosciences and as vice president of business development and scientific collaboration at Genospectra.
 
Mahtani holds a PhD in genetics from Stanford University.
 

 
Affymetrix has promoted Kevin King to president of the company from his previous post as vice president of life sciences and executive vice president. King joined Affy in January of this year. Prior to that, he was CEO and president of Thomson Healthcare and also held executive-level roles at GE Healthcare and Hewlett-Packard.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.